Nautilus, Inc. v. Biosig Instruments, Inc.

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Thursday, November 9, 2023

The gross proceeds from the offering are expected to be approximately $2.5 million.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $2.5 million.
  • BioSig intends to use the net proceeds of this offering for working capital and general corporate purposes.
  • The securities described above are being offered by BioSig pursuant to a shelf registration statement on Form S-3 (File No.
  • The securities offered in the registered direct offering are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP

Retrieved on: 
Tuesday, November 7, 2023

Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe.

Key Points: 
  • Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe.
  • Since April 2022, he has served on the BioSig Board of Directors and as Chairman of the nominating and corporate governance committee.
  • “Fred is well-known as a key executive leader in the global medical device industry.
  • Mr. Hrkac currently serves on the board of Serres in Helsinki, Finland, and Spineart in Geneva, Switzerland as chairman of the board.

BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care

Retrieved on: 
Thursday, November 2, 2023

Harnessing the power of automation, PURE EP™’s latest software features debut unique algorithms that unlock signal data for electrophysiologists conducting even the most challenging ablation procedures.

Key Points: 
  • Harnessing the power of automation, PURE EP™’s latest software features debut unique algorithms that unlock signal data for electrophysiologists conducting even the most challenging ablation procedures.
  • "Our commitment to innovation and delivering exceptional patient care drives our ongoing collaboration with BioSig,” said Hicham El Masry, M.D., FHRS, Cardiac Electrophysiologist at Mayo Clinic-Phoenix.
  • “The integration of PURE EP™'s advanced software features further reinforces our dedication to providing the best possible healthcare solutions for our patients.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI

Retrieved on: 
Wednesday, November 1, 2023

Kenneth Londoner, Chairman and CEO of BioSig, commented, “We are pleased to add five  utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad.

Key Points: 
  • Kenneth Londoner, Chairman and CEO of BioSig, commented, “We are pleased to add five  utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad.
  • Our robust patent protection and well-constructed claims cover BioSig’s first mover advantage for our novel PURE EP™ Platform.”
    U.S. Patent Application No.
  • 11,737,699 granted on August 29, 2023 and is entitled “Systems and Methods for Performing Electrophysiology (EP) Signal Processing.” The patent describes and claims methods and systems for producing a clean unipolar signal.
  • 1 allowed and 1 pending U.S. patent applications directed to artificial intelligence (AI)

Automated test equipment market size to grow by USD 2.04 billion between 2022 and 2027 | The market growth in the consumer electronics segment will be significant - Technavio

Retrieved on: 
Wednesday, November 1, 2023

The market growth in the consumer electronics segment will be significant during the forecast period.

Key Points: 
  • The market growth in the consumer electronics segment will be significant during the forecast period.
  • Factors such as the increase in disposable incomes, reduced cost of consumer electronics, and changing lifestyles in developing countries have been crucial in fueling the growth of the segment.
  • Charts & data tables about market and segment sizes for a historic period of five (2017-2021) years have been covered in this report.
  • However, the continuous increase in raw material prices and increasing import duties are hindering the growth of the market.

BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals

Retrieved on: 
Thursday, August 24, 2023

On July 20, 2023, we announced the inclusion of BioSig AI Sciences, Inc., a majority owned subsidiary of the Company (“BAIS”), in Nvidia’s Inception partnership program, providing our team access to engineering and technology support.

Key Points: 
  • On July 20, 2023, we announced the inclusion of BioSig AI Sciences, Inc., a majority owned subsidiary of the Company (“BAIS”), in Nvidia’s Inception partnership program, providing our team access to engineering and technology support.
  • On July 23, 2023, BAIS completed its seed round of funding of $2.2 million.
  • BAIS has identified numerous opportunities to bring our proprietary AI platform to market.
  • The leading hospitals are looking for entrepreneurial and agile emerging market participants to test and adopt AI based solutions.

BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations

Retrieved on: 
Wednesday, August 23, 2023

Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.

Key Points: 
  • Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.
  • BioSig has made the move to a subscription model so that electrophysiologists and cardiology departments can access the latest features with the ability to customize the rich suite of PURE EP™ software capabilities to suit their needs.
  • During the conference, research conceptualized and spearheaded by Cleveland Clinic’s world-class physician faculty highlighted the PURE EP™ Platform’s ability to optimize ablation procedures.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases

Retrieved on: 
Tuesday, August 22, 2023

The novel software features were successfully leveraged for the first time during patient cases conducted at the Kansas City Heart Rhythm Institute (“KCHRI”).

Key Points: 
  • The novel software features were successfully leveraged for the first time during patient cases conducted at the Kansas City Heart Rhythm Institute (“KCHRI”).
  • “With these new features, we enhance PURE EP™’s existing capabilities, providing electrophysiologists with pure, unadulterated cardiac signals in real time,” said Zachary Koch, Principal Advisor of Product Development at BioSig.
  • “PURE EP™’s capabilities have already been instrumental in improving our workflows,” said Dhanunjaya “DJ” Lakkireddy, M.D., Executive Medical Director at the KCHRI.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

BioSig AI Sciences Receives $2.2 Million in Seed Funding to Advance Development of Artificial Intelligence Applications

Retrieved on: 
Tuesday, July 25, 2023

Westport, CT, July 25, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the completion of a seed funding round raising $2.2 million for BioSig AI Sciences, Inc. (“BAIS”), a subsidiary of the Company.

Key Points: 
  • Westport, CT, July 25, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the completion of a seed funding round raising $2.2 million for BioSig AI Sciences, Inc. (“BAIS”), a subsidiary of the Company.
  • BAIS intends to join BioSig’s world class technology team with external partners and collaborators to advance the research and development of an artificial intelligence (“AI”) medical device platform.
  • “Our current platform and relationships have created interest and excitement and our development team are making demonstrations for early adopters” added Londoner.
  • BioSig and Reified Labs’ initial AI collaboration, which began in 2019, has resulted in multiple patent applications to date and a research publication on AI-enhanced electrocardiogram lead placement mapping.

BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals

Retrieved on: 
Thursday, July 20, 2023

NVIDIA Inception helps leading emerging-growth companies during critical stages of product development, prototyping and deployment.

Key Points: 
  • NVIDIA Inception helps leading emerging-growth companies during critical stages of product development, prototyping and deployment.
  • Partners are qualified to receive engineering guidance, technical training, hardware and software support, co-marketing, and exposure to the NVIDIA investment community.
  • As BAIS advances research and development of its AI medical device platform, it intends to draw on NVIDIA’s wealth of resources including developer application frameworks and domain-specific AI computing for building medical devices.
  • “We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and AI across industries,” said Ken Londoner, Chairman, CEO and Founder of BioSig.